This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NeoStem To Present At Multiple January Conferences

Stocks in this article: NBS

NEW YORK, Jan. 2, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), will present at multiple upcoming conferences in January.

ECI's Scale-Up and Manufacturing of Cell-Based Therapies III

  • Date and Time: Tuesday, January 7, 2014, 3:05 PM PST
  • Venue: Hyatt Regency, San Diego, California
  • Session: Engineering a process for commercial success – strategic considerations and technology alternatives
  • Speaker: Brian Hampson, MS, Senior Director, Engineering & Innovation of PCT

Biotech Showcase 2014

  • Date and Time: Monday, January 13, 2014, 11:30 AM PST
  • Venue: Parc 55 Wyndham San Francisco – Union Square, San Francisco, California
  • Session: Company Presentation
  • Speaker: Robert A. Preti, PhD, President of PCT, Chief Scientific Officer of NeoStem

7 th Annual OneMedForum

  • Venue: The Westin San Francisco Market Street, San Francisco, California
  • Presentation Topics: Company Presentations
  • Presentation #1 Date and Time: Monday, January 13, 2014, 11:50 AM PST
  • Presentation #1 Speaker: Robin L. Smith, MD, MBA, Chairman and CEO of NeoStem
  • Presentation #2 Date and Time: Tuesday, January 14, 2014, 9:50 AM PST
  • Presentation #2 Speaker: Andrew L. Pecora, MD, FACP, Chief Visionary Officer of NeoStem

Alliance for Regenerative Medicine's 4 th Annual State of the Industry Briefing

  • Date and Time: Monday, January 13, 2014, 8:00 AM PST
  • Venue: Parc 55 Wyndham San Francisco – Union Square, San Francisco, California
  • Session: Key Clinical Data Inflection Points for 2014 Panel
  • Panelist: Andrew L. Pecora, MD, FAHA, Chief Visionary Officer of NeoStem

Noble Financial Capital Markets Tenth Annual Equity Conference

  • Date and Time: Monday, January 20, 2014 at 10:00 AM EST
  • Venue: Club Med Sandpiper Bay, Sandpiper Bay, Florida
  • Session: Company Presentation
  • Moderator: Robin L. Smith, MD, MBA, Chairman and CEO of NeoStem

Ninth International Conference on Cell Therapy for Cardiovascular Disease

  • Venue: Vivian and Seymour Milstein Family Heart Center, New York, New York
  • Session #1 Date and Time: Thursday, January 23, 2014, 9:28 AM EST
  • Session #1: AMR-001 and PreSERVE Study: Autologous CD34+ Cells for AMI
  • Session #1 Speaker: Jonathan Sackner-Bernstein, MD, FACC, Vice President, Clinical Development of NeoStem
  • Session #2 Date and Time: Friday, January 24, 2014, 10:30 AM EST
  • Session #2: Clinical Science and Pivotal Studies: Durable Partnerships in Regenerative Medicine
  • Session #2 Discussant: Douglas W. Losordo, MD, FACC, FAHA, Chief Medical Officer of NeoStem

About NeoStem, Inc.

NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs